Coverage
-
May 12, 2026
A New Jersey appellate panel on Tuesday pushed back on an investor's insistence that his complaint over Bristol-Myers Squibb's $74 billion acquisition of Celgene satisfied pleading standards for securities lawsuits, echoing a trial court judge's concern that claims of disclosure requirement shortfalls sounded more in fraud than negligence.
1 other articles on this case.
View all »